Marinus Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 165
- Market Cap
- $80.9M
- Introduction
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.
A Clinical Trial of Oral Ganaxolone in Women With Postpartum Depression
- Conditions
- Pregnancy ComplicationsPostpartum DisorderDepressive DisorderDepression, PostpartumBehavioral SymptomsMental DisorderDepressionMood DisordersPostpartum BluesPPD
- Interventions
- Drug: PlaceboDrug: Ganaxolone
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Marinus Pharmaceuticals
- Target Recruit Count
- 84
- Registration Number
- NCT03460756
- Locations
- 🇺🇸
Marinus Research Site, Richmond, Virginia, United States
Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus
- Conditions
- EpilepsyStatus EpilepticusConvulsive Status EPILEPTICUSNon Convulsive Status Epilepticus
- Interventions
- Drug: IV Placebo, non-activeDrug: IV Ganaxolone active
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- Marinus Pharmaceuticals
- Target Recruit Count
- 17
- Registration Number
- NCT03350035
- Locations
- 🇺🇸
Duke Medical Center, Durham, North Carolina, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Nicklaus Children's Hospital, Miami, Florida, United States
A Clinical Trial of Intravenous (IV) Ganaxolone in Women With Postpartum Depression
- Conditions
- DepressionMood DisordersMental DisordersDepressive DisorderPuerperal DisordersPostpartumBehavioral SymptomsPPDDepression, PostpartumPregnancy Complications
- Interventions
- Drug: GanaxoloneDrug: Placebo
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Marinus Pharmaceuticals
- Target Recruit Count
- 91
- Registration Number
- NCT03228394
- Locations
- 🇺🇸
Marinus Research Site, Richmond, Virginia, United States
A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures
- First Posted Date
- 2015-08-11
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Marinus Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT02519439
- Locations
- 🇺🇸
Bluegrass Epilepsy Research, LLC, Lexington, Kentucky, United States
🇺🇸Minneapolis Clinic of Neurology, Golden Valley, Minnesota, United States
🇺🇸Neurological Research Institute, Santa Monica, California, United States
Open-Label PoC Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies
- First Posted Date
- 2015-02-09
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Marinus Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT02358538
- Locations
- 🇺🇸
Center for Rare Neurological Diseases, Norcross, Georgia, United States
🇮🇹Bambino Gesu Children's Hospital, IRCCS, Rome, Italy
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension
- Conditions
- Drug Resistant Partial Onset Seizure
- Interventions
- Drug: ganaxoloneDrug: Placebo
- First Posted Date
- 2013-10-16
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Marinus Pharmaceuticals
- Target Recruit Count
- 405
- Registration Number
- NCT01963208
- Locations
- 🇺🇸
The MORE Foundation, Sun City, Arizona, United States
🇺🇸Clinical Trials Inc., Little Rock, Arkansas, United States
🇦🇺The Royal Melbourne Hospital, Parkville, Victoria, Australia
Ganaxolone Treatment in Children With Fragile X Syndrome
- First Posted Date
- 2012-11-12
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Marinus Pharmaceuticals
- Target Recruit Count
- 59
- Registration Number
- NCT01725152
- Locations
- 🇧🇪
Antwerp University Hospital, Edegem, Belgium
🇺🇸M.I.N.D. Institute at University of California at Davis Medical Center, Sacramento, California, United States
Ganaxolone in Posttraumatic Stress Disorder (PTSD)
- First Posted Date
- 2011-04-21
- Last Posted Date
- 2022-12-29
- Lead Sponsor
- Marinus Pharmaceuticals
- Target Recruit Count
- 112
- Registration Number
- NCT01339689
- Locations
- 🇺🇸
White River Junction VA Medical Center/ Dartmouth College, White River Junction, Vermont, United States
🇺🇸Washington DC VA Medical Center/ Uniformed Services University of the Health Services, Washington, District of Columbia, United States
🇺🇸Durham VA Medical Center /Duke University Medical Center, Durham, North Carolina, United States
A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- Marinus Pharmaceuticals
- Target Recruit Count
- 11
- Registration Number
- NCT01002820
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸Riddle Health Care Center II, Philadelphia, Pennsylvania, United States
🇺🇸Thomas Jefferson University, Comprehensive Epilepsy Center, Philadelphia, Pennsylvania, United States
Open-label Extension to Protocol 1042-0600
- First Posted Date
- 2007-08-07
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Marinus Pharmaceuticals
- Target Recruit Count
- 123
- Registration Number
- NCT00512317
- Locations
- 🇺🇸
University of California-Davis, Sacramento, California, United States
🇺🇸Southern Illinois University Medical Center, Springfield, Illinois, United States
🇺🇸Arkansas Epilepsy Program, Little Rock, Arkansas, United States